US-based cancer biotherapeutics developer Werewolf Therapeutics has completed a $72m series B round backed by Taiho Ventures, the corporate venturing arm of pharmaceutical firm Taiho Pharmaceutical.
Investment Manager
Werewolf is working on treatments to bolster the body’s immune response to cancer. They will be administered in an inactive form – either as a monotherapy or combination therapy – and only activate once the molecules enter the tumour microenvironment.
The series B capital has been allocated to moving two of the company’s drug candidates through phase 1 studies and readying several additional programmes for Investigational New Drug applications.
Deerfield principal Elise Wang and Derek DiRocco, a partner at RA Capital, have joined Werewolf’s board of directors in conjunction with the round.
The company was launched with an undisclosed amount of seed capital from MPM Capital and raised $56m in a late 2019 series A round co-led by MPM Capital and Longwood Fund that included Taiho Ventures, UPMC Enterprises, Arkin Bio Ventures and DC Investment Partners.
The original version of this article appeared on our sister site, Global University Ventures.